论文部分内容阅读
目的：为探讨Cyfra21－1在非小细胞肺癌（NSCLC）患者治疗前后含量变化并观察其与临床症状变化的相互关系,并藉此来评估治疗效果及预后。方法：用放射免疫法测定51例经手术病理确诊的NSCLC病人血Cyfra21－1含量。术前检测1次，术后分两组，手术根治组34例，术后1d，7d,1个月，3个月分别抽血测定，病情稳定后每3月1次；姑息切除化疗组17例，术后测定1次，每次化疗前后定期检测，两组测定值用统计学处理（T检验）。结果：手术根治组NSCLC术前Cyfra21－1平均值（7．769±5．915）ng／ml，术后（1．870±1．406）ng／ml（x±s），本前术后对照（t检验）有高度显著性意义（P＜0．01）。姑息性切除化疗组化疗前Cyfra21—1平均值（6．860±3.6.69）ng／m；（x±s）化疗后（3.134±1．957）ng／ml，化疗后Cyfra21－1水平高度显著性下降（P＜0.01）。两组治疗后都有显著性下降，但手术根治组下降幅度更大.结论：Cyfra21－1是NSCLC高度敏感性、特异性的肿瘤标志物，本组敏感性为94．1％，它的含量变化与临床症状变化是正相关，它不但可用来诊断NSCLC,而且完全可以单独应用于治疗监测，评估治疗效果及预后的判定。
Objective: To investigate the changes of Cyfra21-1 in patients with non-small cell lung cancer (NSCLC) before and after treatment, and to observe the relationship between Cyfra21-1 and clinical symptoms, and to evaluate the therapeutic effect and prognosis. Methods: The Cyfra21-1 levels in 51 NSCLC patients diagnosed by pathology were determined by radioimmunoassay. Preoperative examination was performed once, postoperatively divided into two groups, 34 patients underwent radical surgery, 1 d, 7 d, 1 month, and 3 months postoperatively; blood was measured at each postoperative month; palliative resection chemotherapy group 17 Cases, measured once after surgery, and before and after each chemotherapy were regularly tested, and the two groups were statistically processed (T-test). Results: The average value of Cyfra21-1 preoperatively (7.769±5.915) ng/ml, and postoperative (1.870±1.406) ng/ml (x±s) in the surgically treated NSCLC group were compared. The control (t test) was highly significant (P < 0.01). The mean value of Cyfra21-1 before chemotherapy in the palliative resection chemotherapy group was (6.860±3.6.69) ng/m; (x±s) chemotherapy was (3.134±1.957) ng/ml, and the Cyfra21-1 level after chemotherapy was highly Significantly decreased (P<0.01). Both groups had significant decrease after treatment, but the radical reduction was greater in the surgical radical group. Conclusion: Cyfra21-1 is a highly sensitive and specific tumor marker of NSCLC. The sensitivity of this group is 94.1%, its content Changes are positively correlated with clinical symptom changes. Not only can they be used to diagnose NSCLC, but they can also be used alone for treatment monitoring, assessment of treatment efficacy and prognosis.